Skyrizi Global Market Opportunities and Strategies to 2035

This report describes and explains the skyrizi market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global skyrizi market reached a value of nearly $13.98 billion in 2025, having grown at a compound annual growth rate (CAGR) of 54.5% since 2020. The market is expected to grow from $13.98 billion in 2025 to $30.77 billion in 2030 at a rate of 17.1%. The market is then expected to grow at a CAGR of 12.1% from 2030 and reach $54.39 billion in 2035.

Growth in the historic period resulted from the increasing incidence of autoimmune disorders, rising demand for biologics, rising demand for personalized and precision medicine and rise in patient access programs. Factors that negatively affected growth in the historic period were high cost of biologic therapies and growing use of alternative biologics in the same indications.

Going forward, the rising prevalence of chronic diseases, rise in aging population, expansions of biopharmaceutical plants and biosimilars production and rising prevalence of psoriasis will drive the growth. Factors that could hinder the growth of the skyrizi market in the future include limited long-term real-world evidence, strict regulatory and prescribing guidelines and impact of trade war and tariffs.

The skyrizi market is segmented by indication into psoriatic disease, crohn's disease and ulcerative colitis. The psoriatic disease market was the largest segment of the skyrizi market segmented by indication, accounting for 69.5% or $9.71 billion of the total in 2025. Going forward, the crohn's disease segment is expected to be the fastest growing segment in the skyrizi market segmented by indication, at a CAGR of 19.4% during 2025-2030.

The skyrizi market is segmented by formulation into pre-filled syringes and vials. The pre-filled syringes market was the largest segment of the skyrizi market segmented by formulation, accounting for 69.5% or $9.71 billion of the total in 2025. Going forward, the vials segment is expected to be the fastest growing segment in the skyrizi market segmented by formulation, at a CAGR of 18.6% during 2025-2030.

The skyrizi market is segmented by distribution channel into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies market was the largest segment of the skyrizi market segmented by distribution channel, accounting for 49.2% or $6.88 billion of the total in 2025. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the skyrizi market segmented by distribution channel, at a CAGR of 20% during 2025-2030.

North America was the largest region in the skyrizi market, accounting for 85% or $11.88 billion of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the skyrizi market will be Asia Pacific and Middle East where growth will be at CAGRs of 43.4% and 43.2% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 35.2% and 30.4% respectively.

The global skyrizi market is highly concentrated, with large players operating in the market. The top competitors in the market made up to 100% of the total market in 2024. AbbVie Inc was the largest competitor with a 100% share of the market.

The top opportunities in the skyrizi markets segmented by indication will arise in the psoriatic disease segment, which will gain $11.01 billion of global annual sales by 2030. The top opportunities in the skyrizi markets segmented by formulation will arise in the pre-filled syringes segment, which will gain $11.01 billion of global annual sales by 2030. The top opportunities in the skyrizi markets segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $7.56 billion of global annual sales by 2030. The skyrizi market size will gain the most in the USA at $11.03 billion.

Market-trend-based strategies for the skyrizi market include focus on expansion of indication approvals for advanced biologic therapies and focus on expanding regulatory approvals for IL-23 inhibitors.

Player-adopted strategies in the skyrizi market include focus on enhancing business operations through drug approval and strategic initiatives.

To take advantage of the opportunities, the analyst recommends the skyrizi companies to focus on expanding multi indication approvals for skyrizi, focus on expanding regulatory approvals for IL 23 inhibitors, focus on crohn’s disease for accelerated growth, focus on expanding vial-based delivery for clinical settings, expand in emerging markets, continue to focus on developed markets, focus on value based and flexible pricing strategies, focus on expanding online pharmacy distribution channels and focus on strengthening stakeholder engagement and clinical expertise.

This product will be delivered within 3-5 business days.